LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

LLY

732.88

+0.07%↑

JNJ

177.5

+0.27%↑

ABBV

211.68

+0.66%↑

UNH

308.79

-0.21%↓

AZN

80.16

+0.34%↑

Search

BioCryst Pharmaceuticals Inc

Geschlossen

BrancheGesundheitswesen

8.28 -0.24

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

8.27

Max

8.46

Schlüsselkennzahlen

By Trading Economics

Einkommen

5.1M

5.1M

Verkäufe

18M

163M

Gewinnspanne

3.113

Angestellte

580

EBITDA

-84M

-62M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+110.59% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

3. Nov. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-88M

1.7B

Vorheriger Eröffnungskurs

8.52

Vorheriger Schlusskurs

8.28

Nachrichtenstimmung

By Acuity

32%

68%

94 / 371 Ranking in Healthcare

BioCryst Pharmaceuticals Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

2. Sept. 2025, 23:07 UTC

Akquisitionen, Fusionen, Übernahmen

Broadwood Partners Plans to Vote Against Staar Sale to Alcon

2. Sept. 2025, 22:10 UTC

Wichtige Markttreiber

Bruker Shares Fall on Convertible Share Offering Aimed at Debt Repayment

2. Sept. 2025, 21:47 UTC

Ergebnisse

Alimentation Couche-Tard Logs Lower Profit, Revenue in 1Q

2. Sept. 2025, 16:52 UTC

Wichtige Markttreiber

CleanCore Solutions Shares Drop After $175 Million Private Investment

2. Sept. 2025, 22:47 UTC

Market Talk

Google, Apple Can Grow AI Deal With Lawsuit Resolved -- Market Talk

2. Sept. 2025, 21:40 UTC

Akquisitionen, Fusionen, Übernahmen

Investors Have to Be Ready for State Capitalism. What Areas to Watch. -- Barrons.com

2. Sept. 2025, 21:07 UTC

Ergebnisse

Couche-Tard 1Q U.S. Same-Store Merchandise Revenue Up 0.4% >ATD.T

2. Sept. 2025, 21:07 UTC

Ergebnisse

Couche-Tard 1Q Canada Same-Store Merchandise Revenue Up 4.1% >ATD.T

2. Sept. 2025, 21:05 UTC

Ergebnisse

Couche-Tard 1Q Rev $17.35B >ATD.T

2. Sept. 2025, 21:05 UTC

Ergebnisse

Couche-Tard 1Q Adj EPS 78c >ATD.T

2. Sept. 2025, 21:05 UTC

Ergebnisse

Couche-Tard 1Q EPS 82c >ATD.T

2. Sept. 2025, 21:05 UTC

Ergebnisse

Couche-Tard 1Q Net $782.5M >ATD.T

2. Sept. 2025, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

2. Sept. 2025, 20:53 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Knight-Swift Transportation Endorses Union Pacific, Norfolk Southern Merger -- Market Talk

2. Sept. 2025, 20:51 UTC

Akquisitionen, Fusionen, Übernahmen

Buffett Dislikes Breakup of Kraft Heinz. It's Been One of His Worst Investments. -- Barrons.com

2. Sept. 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

2. Sept. 2025, 20:27 UTC

Ergebnisse

NIO Stock Rises After Second-Quarter Loss Narrows -- Barrons.com

2. Sept. 2025, 20:24 UTC

Akquisitionen, Fusionen, Übernahmen

Air Lease Is Going Private. Why Boeing Stock Is Up. -- Barrons.com

2. Sept. 2025, 20:18 UTC

Akquisitionen, Fusionen, Übernahmen

Procter & Gamble Does Not Endorse Tutanota's Unsolicited Mini-Tender Offer >PG

2. Sept. 2025, 20:17 UTC

Akquisitionen, Fusionen, Übernahmen

Procter & Gamble: Tutanota Says It Expects to Extend Offer for Successive Periods of Up to 180 Days Until Market Price Exceeds Offer Price >PG

2. Sept. 2025, 20:16 UTC

Akquisitionen, Fusionen, Übernahmen

Procter & Gamble: 'Shareholders Who Tender Their Shrs in the Offer Will Receive a Below-Market Price' >PG

2. Sept. 2025, 20:16 UTC

Akquisitionen, Fusionen, Übernahmen

Procter & Gamble: Offer by Tutanota Is to Purchase Up to 500,000 Shrs at $128 Each

2. Sept. 2025, 20:15 UTC

Akquisitionen, Fusionen, Übernahmen

Procter & Gamble Has Been Notified of Unsolicited Mini-Tender Offer by Tutanota >PG

2. Sept. 2025, 19:55 UTC

Ergebnisse

GM Had a Record Month of EV Sales. A 'Collapse' Is Coming. -- Barrons.com

2. Sept. 2025, 19:50 UTC

Akquisitionen, Fusionen, Übernahmen

Food Giants Are Struggling. Could Mergers, Spinoffs, and Activist Stakes Help? -- Barrons.com

2. Sept. 2025, 19:09 UTC

Market Talk

Oil Futures Gain on Geopolitical Premium -- Market Talk

2. Sept. 2025, 19:00 UTC

Market Talk

U.S. Natural Gas Futures Recover $3 Level -- Market Talk

2. Sept. 2025, 18:12 UTC

Market Talk

Gold Pushes To New Record -- Market Talk

2. Sept. 2025, 17:04 UTC

Market Talk

Philip Morris Riding Smoke-Free Products to Higher Margins -- Market Talk

2. Sept. 2025, 16:57 UTC

Akquisitionen, Fusionen, Übernahmen

Air Lease Is Going Private. Why Boeing Stock Is Up. -- Barrons.com

Peer-Vergleich

Kursveränderung

BioCryst Pharmaceuticals Inc Prognose

Kursziel

By TipRanks

110.59% Vorteil

12-Monats-Prognose

Durchschnitt 17.5 USD  110.59%

Hoch 30 USD

Tief 12 USD

Basierend auf 6 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für BioCryst Pharmaceuticals Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

6 ratings

6

Buy

0

Halten

0

Sell

Stimmung

By Acuity

94 / 371 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Unterdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.